Clinical studies showed teduglutide to increase urine production and reduce need for parenteral support volume in patients with short bowel syndrome (SBS) with intestinal failure, increasing intestinal wet weight absorption and reducing diarrhea. However, the effects of teduglutide on parenteral support vary among patients. We performed a post-hoc analysis of a phase 3 placebo-controlled study to identify characteristics of patients in whom teduglutide has the largest effects on parenteral support volume response.